Horizon Discovery expands CRISPR licence with ERS Genomics
UK-based genomics company Horizon Discovery has expanded its licence coverage for use of the CRISPR gene-editing technology.
In a deal announced today, December 5, Horizon Discovery amended its licence with ERS Genomics to enable the company to use CRISPR in new areas across its products and services.
ERS Genomics was launched to provide access to the CRISPR/Cas9 IP held by inventor Emmanuelle Charpentier.
Horizon Discovery has been granted research rights for industrial production of certain animals, among other uses.
The amended agreement also includes provision for either a joint venture or a spin-out in which Horizon Discovery will have a significant minority interest.
The new entity will be able to use CRISPR for its own internal research without an additional licence being required.
In addition, Horizon Discovery was granted rights to allow partners to make and sell its products.
This is the second time this year that Horizon Discovery has broadened its licence with ERS Genomics.
In January, the licence was amended to include the full commercial rights for use of CRISPR, meaning that Horizon has the right to use CRISPR-edited cell lines in biomanufacturing.
The original agreement was signed in 2014, focusing on use of CRISPR technology for research purposes including into development and sale of tool kits and reagents for use in research and diagnostics.
Darrin Disley, CEO of Horizon Discovery, said: “Horizon was the first company to take a licence for CRISPR from ERS Genomics, and currently holds what we believe to be the broadest access to this technology.”
Eric Rhodes, CEO of ERS Genomics, added: “By enabling Horizon’s continued expansion into novel markets through this expanded licence, both organisations are able to gain access to additional revenue streams.”
Life Sciences IP Review is hosting a conference tomorrow, December 6, covering CRISPR and many other exciting issues in the life sciences arena. Click here to register for the event, which is being held in London.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
